New vaccine technology to boost immunity against brain tumors
Novel nano-vaccine technology for inducing immunity against gliomas
This study is testing a new type of vaccine designed to boost the immune system's ability to fight gliomas, a kind of brain cancer, and patients may have the chance to join trials to see how well this exciting treatment works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10879053 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine technology aimed at enhancing the immune response against gliomas, a type of brain cancer. The approach involves using synthetic high-density lipoprotein nanodiscs to deliver specific antigens and adjuvants to immune cells, promoting a strong and lasting T-cell response. By utilizing a genetically engineered mouse model that mimics human gliomas, the researchers aim to create a powerful vaccine that can effectively stimulate the immune system to fight these tumors. Patients may have the opportunity to participate in trials that test this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with gliomas, particularly those with the mutant isocitrate-dehydrogenase-1 (IDH1-R132H) variant.
Not a fit: Patients with gliomas that do not express the IDH1-R132H mutation or those with advanced-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new and effective treatment option for patients with gliomas, potentially improving their survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using similar vaccine technologies to stimulate immune responses in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Moon, James J. — University of Michigan at Ann Arbor
- Study coordinator: Moon, James J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.